Primary erectile dysfunctions treated with a controversial new drug
A new treatment for erectile disorders is gaining momentum in Australia after being developed by researchers from Imperial College London.
The Australian Medical Association has welcomed the new drug as a promising new treatment option for patients suffering from erectile disfunction.
It comes after research by the University of Sydney’s Department of Psychiatry revealed that patients with erectile disorder were more likely to have erectile problems than healthy men.
Researchers said the drug could treat erectile function in men who had undergone the surgery for hypospadias.
They said the medication could be used to treat men who have undergone hyposchisis surgery, or those who have had hyposembolism, a type of blood clot that can be deadly.
The treatment is being developed as part of the first phase of the National Erectile Dysfunction Survey, which is a multi-centre study to study the impact of erectile disease on men.
The new treatment is the first to use the new blood test, which can detect changes in blood flow to the penis, and to be administered by injection.
“We’re trying to make this as easy as possible for people to use as much as we can, and that’s a challenge for this kind of technology,” said Dr Daniel Mottram from Imperial’s Department for Psychiatry and Sexual Medicine.
Dr Mottrams team used a computer algorithm to map the blood flow changes to the entire penis and found that it increased from 4 to 12 millilitres in a patient with erectigonal dysfunction.
He said the new treatment could be effective for up to 10 percent of men, and if used correctly, could reduce the chances of erecting again.
Dr Adam Lachapelle, who led the study, said the results were encouraging, but cautioned that it was still unclear how long the drug would last.
“This is an area where we have a lot of work to do before we can say we have seen a big benefit, but I think it’s a step in the right direction,” he said.
Dr Lachaps research was published in the British Medical Journal (BMJ).
Dr Mettram said there were still a number of unanswered questions about the drug, including its safety and effectiveness.
“Our hope is that we can find some early indications that this is a treatment that is safe, effective and can reduce the risk of erections in men,” he added.
The team said the treatment could also be used in men with an existing condition such as erectile polycystic ovary syndrome.